Research Topics
Genomes and GenesSpecies | Thomas PabstSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller
Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, USA
Blood 100:998-1007. 2002..1 target genes. This is the first report of mutations in the PU.1 gene in human neoplasia and suggests that disruption of PU.1 function contributes to the block in differentiation found in AML patients...
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabineThomas Pabst
Department of Medical Oncology, University Hospital, Bern, Switzerland
Blood 119:5367-73. 2012..The HOVON-42 study is registered under The Netherlands Trial Registry (www.trialregister.nl) as #NTR230...
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisT Pabst
Department of Medical Oncology and Clinical Research, University Hospital Bern and University Bern, Bern, Switzerland
Br J Cancer 100:1343-6. 2009..In a multivariable analysis, only double -- but not single -- CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations...- Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemiaThomas Pabst
Department of Medical Oncology, University Hospital, Bern, Switzerland
J Clin Oncol 26:5088-93. 2008..Whereas familial AML is considered a rare event, the frequency of CEBPA germline mutations in AML is not known... - Transcriptional dysregulation during myeloid transformation in AMLT Pabst
Institute of Medical Oncology, University Hospital, Bern, Switzerland
Oncogene 26:6829-37. 2007.... - Complexity of CEBPA dysregulation in human acute myeloid leukemiaThomas Pabst
Department of Oncology, University Hospital, Bern, Switzerland
Clin Cancer Res 15:5303-7. 2009..The currently available data are persuasive evidence that impaired CEBPA function contributes directly to the development of AML, whereas restoring CEBPA function represents a promising target for novel therapeutic strategies in AML... - Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemiaJulian A Schardt
Department of Medical Oncology, University Hospital Bern and University of Bern, Switzerland
J Cell Mol Med 14:1509-19. 2010.... - Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemiaJulian A Schardt
Departments of Medical Oncology and Clinical Research, University Hospital Bern, Bern, Switzerland
Clin Cancer Res 15:3834-41. 2009..Previous studies suggest that the unfolded protein response is activated in some cancer cell lines and involved in tumor development. The role of the unfolded protein response during leukemogenesis is unknown thus far... - Complexity of miR-223 regulation by CEBPA in human AMLMarianne Eyholzer
Institute of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010 Bern, Switzerland
Leuk Res 34:672-6. 2010..Our results suggest that miR-223 suppression in AML is caused by impaired miR-223 upstream factors... - Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AMLSimon Haefliger
Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
Blood 117:5931-40. 2011..Our results indicate a novel role of PDI as a member of the ER stress-associated complex mediating blocked CEBPA translation and thereby suppressing myeloid differentiation in AML patients with activated unfolded protein response (UPR)... - The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patientsSarah Mans
Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland
Blood 120:2690-9. 2012..006). Our data indicate that vasostatin is released from cell-surface CRT and impairs differentiation of myeloid cells and vascularization of the bone marrow microenvironment... - Lineage-specific transcription factor aberrations in AMLBeatrice U Mueller
Department of Internal Medicine, University Hospital, 3010, Bern, Switzerland
Cancer Treat Res 145:109-25. 2010..Here, we intend to review recent findings on aberrations in lineage-restricted transcription factors as observed in patients with acute myeloid leukemia (AML)... - Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosisJosé Fos
Department of Internal Medicine and Clinical Research, University of Bern, Bern, Switzerland
Blood 117:4881-4. 2011..These data indicate that suppressed CEBPA function is associated with favorable prognosis in NK-AML patients... - ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expressionBeatrice U Mueller
Department of Internal Medicine, University Hospital, 3010 Bern, Switzerland
Blood 107:3330-8. 2006..This is the first report to show that PU.1 is suppressed in acute promyelocytic leukemia, and that ATRA restores PU.1 expression in cells harboring t(15;17)... - Heterozygous deletion of the PU.1 locus in human AMLNicola Bonadies
Department of Internal Medicine and Clinical Research, University Hospital, and University of Bern, Bern, Switzerland
Blood 115:331-4. 2010..1 locus. Consistently, PU.1 expression in this patient was markedly reduced. Our study suggests that heterozygous deletion of the PU.1 locus can be associated with human AML... - Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst
Institute of Medical Oncology, University Hospital, Berne, Switzerland
Br J Haematol 133:400-2. 2006..Here, no CEBPA mutation in 95 CML-BC patients was found, suggesting a limited role, if any, of CEBPA mutations in this disorder... - Activation of the unfolded protein response in human acute myeloid leukemiaJulian A Schardt
Department of Medical Oncology, University Hospital, Bern, Switzerland
Methods Enzymol 489:227-43. 2011..From a more clinical point of view, the presence of activated UPR in AML patient samples was found to be associated with a favorable disease course... - CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)Daniel Helbling
Department of Clinical Research, University Hospital, Berne, Switzerland
Blood 106:1369-75. 2005..Inhibition of calreticulin by siRNA restored CEBPA levels. Our results suggest that modulation of CEBPA by calreticulin represents a novel mechanism involved in the differentiation block in CBFB-SMMHC AML... - Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiencyStefano Fontana
Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
Transfusion 46:1408-16. 2006..Individual adaptation of processed patient's blood volume (PBV) should reduce number and/or duration of autologous peripheral blood progenitor cell (PBPC) collections... - Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemiaB U Mueller
Department of Internal Medicine, University Hospital, Bern, Switzerland
Br J Cancer 94:1918-20. 2006..1 gene. We found no genomic alteration of the PU.1 gene suggesting that PU.1 mutations are not likely to be common in B-ALL... - C/EBPalpha and the pathophysiology of acute myeloid leukemiaBeatrice U Mueller
Department of Internal Medicine, University Hospital, Switzerland
Curr Opin Hematol 13:7-14. 2006..Restoring C/EBPalpha function represents a promising target for novel therapeutic strategies in acute myeloid leukemia... - The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potentialIsabelle von Grünigen
Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
Leuk Res 36:1325-9. 2012..These data suggest that ASCT is associated with unfavorable outcome in AML patients with high levels of mobilized peripheral CD34+ cells... - Pneumococcal vaccination in splenectomised cancer patientsAurelius G Omlin
Department of Medical Oncology, University Hospital, 3010 Bern, Switzerland
Eur J Cancer 41:1731-4. 2005..Repeated assessments of the pneumococcal vaccination status increased the rate of vaccination... - The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of CalreticulinDaniel Helbling
Institute of Medical Oncology, University Hospital, CH-3010 Bern, Switzerland
Proc Natl Acad Sci U S A 101:13312-7. 2004..These results identify CEBPA as a key target of the leukemic fusion protein AME and suggest that modulation of CEBPA by CRT may represent a mechanism involved in the differentiation block in AME leukemias... - PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer elementN Bonadies
Department of Internal Medicine and Clinical Research, University Hospital Bern, University of Bern, Bern, Switzerland
Oncogene 29:1062-72. 2010..1 mRNA expression. This study suggests that changes of a single base pair in a distal element critically affect the regulation of the tumor suppressor gene PU.1 thereby contributing to the development of AML... - Risk assessment in patients with acute myeloid leukemia and a normal karyotypeMarianne Bienz
Institute of Medical Oncology and the Laboratory for Molecular Diagnostics, Department of Hematology, University of Berne, CH-3010 Berne, Switzerland
Clin Cancer Res 11:1416-24. 2005..CONCLUSIONS: Assessment of CEBPA mutations, FLT3-ITD, and BAALC expression permits to split normal-karyotype AML into clinically distinct subgroups... - Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller
Blood 101:2074. 2003 - Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cellsPeggy Kirstetter
European Molecular Biology Laboratory, Mouse Biology Unit, Monterotondo 00016, Italy
Cancer Cell 13:299-310. 2008..Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature shared with MLL-AF9-transformed AML...